BCR/Integrin Interaction in CLL: A Physiologic Remnant with Clinical Relevance

CD49d, the alpha chain of the very late antigen- 4 (VLA-4) integrin, has a negative prognostic impact in chronic lymphocytic leukemia treated with the Bruton's tyrosine kinase (BTK) inhibitors, ibrutinib and acalabrutinib. Despite BTK inhibition, VLA-4 remains inside-out activated via B-cell receptor, an activation dampened by phosphoinositide 3-kinase inhibitors. Evaluation of CD49d expression in patients starting BTK inhibitor therapy may improve their prognostic stratification.

Automated summary

CD49d, the alpha chain of VLA-4 integrin, has a negative impact in CLL patients treated with BTK inhibitors. Evaluating CD49d expression can improve prognostic stratification.